Glycostem approaches collaborations and licensing deals with the aim of addressing the needs and aligning the contributions of both partners. The ultimate goal for our team is to define the combined strengths of such partnerships to create promising therapeutics which lead to better outcomes for people suffering from cancer.
Harboring sound scientific, clinical and product development knowledge we lay the groundwork for identifying and evaluating appropriate partners whose assets and expertise present a beneficial and complementary asset to our company expertise.
We build bridges and maintain close relationships with our partners. Over the entire lifecycle of each project, our team of experts provides continuous support across all functions and ensures that respective tasks are performed to the highest standards possible and that the partnership is evolving to the full satisfaction of both parties.
Commercialization agreement - Glycostem Therapeutics B.V. and medac GmbH, an international pharmaceutical company based in Germany, will partner to commercialize Glycostem’s lead product, oNKord®.
oNKord® is currently in a phase I/II clinical trial across 10 hospitals in 5 European countries.
Co-development and Commercialization agreement – Two agreements have been signed with a Korean pharmaceutical company inno.N. The objective of both agreements is treatment of hard-to-treat cancers through the use of non-manipulated and genetically manipulated Natural Killer cells(NK cells). The collaboration will focus on two activities: An exclusive commercialization agreement for oNKord® for Korea and Japan and a co-development agreement for a CAR-NK product for which the undisclosed Korean pharmaceutical company has global commercialization rights. Read further